Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Sygnis Pharma
Sygnis Pharma
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Analysis
SYGNIS AG announces the launch of TrueHelix
The first tool on the TrueHelix platform addresses sample contamination, a key pitfall in NGS workflows
Ingredients
SYGNIS AG reinforces its proteomics portfolio with two patents granted in Europe and China
Granted patents confirm innovation and novelty of proteomics product range
Research & Development
Sygnis strengthens management team with appointment of Heikki Lanckriet
He joins the DNA amplification and sequencing firm as joint CEO and Chief Scientific Officer
Subscribe now